Evidence map›Paper›PMID 33233339›Full record

ReviewAntibiotics (Basel, Switzerland)2020

Can We Exploit β-Lactamases Intrinsic Dynamics for Designing More Effective Inhibitors?

Eleonora Gianquinto, Donatella Tondi, Giulia D'Arrigo, Loretta Lazzarato, Francesca Spyrakis

Open access · goldAbstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Localising individual atoms of tryptophan side chains in the metallo-Magnetic resonance (Gottingen, Germany) · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Eleonora GianquintoDepartment of Drug Science and Technology, University of Turin, via Giuria 9, 10125 Turin, Italy.
Donatella TondiDepartment of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125 Modena, Italy.ORCID 0000-0002-5195-5531
Giulia D'ArrigoDepartment of Drug Science and Technology, University of Turin, via Giuria 9, 10125 Turin, Italy.
Loretta LazzaratoDepartment of Drug Science and Technology, University of Turin, via Giuria 9, 10125 Turin, Italy.ORCID 0000-0001-7100-8593
Francesca SpyrakisDepartment of Drug Science and Technology, University of Turin, via Giuria 9, 10125 Turin, Italy.ORCID 0000-0002-4016-227X
University of Turin · ITUniversity of Modena and Reggio Emilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β-lactamases (BLs) represent the most frequent cause of antimicrobial resistance in Gram-negative bacteria. Despite the continuous efforts in the development of BL inhibitors (BLIs), new BLs able to hydrolyze the last developed antibiotics rapidly emerge. Moreover, the insurgence rate of effective mutations is far higher than the release of BLIs able to counteract them. This results in a shortage of antibiotics that is menacing the effective treating of infectious diseases. The situation is made even worse by the co-expression in bacteria of BLs with different mechanisms and hydrolysis spectra, and by the lack of inhibitors able to hit them all. Differently from other targets, BL flexibility has not been deeply exploited for drug design, possibly because of the small protein size, for their apparent rigidity and their high fold conservation. In this mini-review, we discuss the evidence for BL binding site dynamics being crucial for catalytic efficiency, mutation effect, and for the design of new inhibitors. Then, we report on identified allosteric sites in BLs and on possible allosteric inhibitors, as a strategy to overcome the frequent occurrence of mutations in BLs and the difficulty of competing efficaciously with substrates. Nevertheless, allosteric inhibitors could work synergistically with traditional inhibitors, increasing the chances of restoring bacterial susceptibility towards available antibiotics.

Indexed as

allosteric enzyme inhibitorsantimicrobial resistancecarbapenemasesdrug designintrinsic dynamicsKPC-2metallo β-lactamasesprotein flexibilityβ-lactamases

Identifiers

PMID33233339
PMCPMC7700307
OpenAlexW3104811569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.